Handelsbanken Fonder Ab Zymeworks Inc. Transaction History

Handelsbanken Fonder Ab

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 03, 2022	SELL	$4.82 - $7.7 $55,430 - $88,550	-11,500 Closed	0 $0
Q2 2021 Aug 03, 2021	SELL	$26.5 - $38.23 $1.86 Million - $2.68 Million	-70,200 Reduced 85.92%	11,500 $399,000
Q1 2021 Apr 29, 2021	BUY	$29.83 - $56.81 $2.24 Million - $4.26 Million	75,000 Added 1119.4%	81,700 $2.58 Million
Q4 2020 Feb 11, 2021	BUY	$39.12 - $54.99 $262,103 - $368,433	6,700 New	6,700 $317,000

296K

Ticker ZYME
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,694,400
Market Cap $872M
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...

Get notified when there are updates to the investment portfolio of Handelsbanken Fonder Ab, based on Form 13F filings with the SEC.

Stay updated on Handelsbanken Fonder Ab with notifications on news.